EIZO (6737) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
18 Mar, 2026Executive summary
Net sales remained flat year-over-year at JPY80.4B, with record V&S market sales but declines in Healthcare, Creative Work, and Amusement segments.
Operating profit decreased 5.2% to JPY3.7B, impacted by higher SG&A expenses and foreign exchange losses.
Profit attributable to owners fell 23.9% year-over-year to JPY4.1B.
Extraordinary profit included a JPY1.1B gain from investment security sales, offset by a JPY0.6B loss from the Noto Peninsula Earthquake.
Financial highlights
Gross profit increased 3.1% year-over-year to JPY26.2B, with gross margin rising to 32.5%.
SG&A expenses rose 4.6% due to wage hikes and R&D investment.
Ordinary profit dropped 28% to JPY4.6B, mainly due to foreign exchange losses.
Cash flows from operating activities were JPY11.5B, with cash and cash equivalents at year-end of JPY21.1B.
Total assets decreased to JPY157.8B, and net assets fell to JPY124.4B.
Outlook and guidance
FY25/FY2026 net sales projected at JPY85B (+5.6%), with operating profit expected to rise to JPY4.8B (+29.5%).
Ordinary profit forecast at JPY6.1B (+33.9%), and profit attributable to owners at JPY4.4B (+6.1%).
Growth anticipated in Japan, Europe, India, and the Middle East, with new product launches and expansion in V&S, Amusement, and Healthcare.
U.S. and China face headwinds from tariffs and economic slowdown.
Dividend per share to increase to JPY110 (post-split), marking the 13th consecutive annual increase.
Latest events from EIZO
- Profits fell on weak demand, but full-year growth and a share split are forecast.6737
Q1 202518 Mar 2026 - Profits and comprehensive income fell sharply, with a modest sales outlook and share split enacted.6737
Q2 202518 Mar 2026 - Profits dropped despite stable sales, with unchanged guidance and a recent share split.6737
Q3 202518 Mar 2026 - Sales and profits fell on European weakness, but margin and new products support future outlook.6737
Q1 202618 Mar 2026 - Healthcare and Amusement drove 2.9% sales growth, but profits were pressured by higher SG&A.6737
Q2 202618 Mar 2026 - Net sales rose, but profit outlook was cut due to higher costs and weak European demand.6737
Q3 202618 Mar 2026